Literature DB >> 24715604

Mapping EQ-5D utility scores from the PedsQL™ generic core scales.

Kamran A Khan1, Stavros Petrou, Oliver Rivero-Arias, Stephen J Walters, Spencer E Boyle.   

Abstract

PURPOSE: The Pediatric Quality of Life Inventory™ (PedsQL™) General Core Scales (GCS) were designed to provide a modular approach to measuring health-related quality of life in healthy children, as well as those with acute and chronic health conditions, across the broadest, empirically feasible, age groups (2-18 years). Currently, it is not possible to estimate health utilities based on the PedsQL™ GCS, either directly or indirectly. This paper assesses different mapping methods for estimating EQ-5D health utilities from PedsQL™ GCS responses.
METHODS: This study is based on data from a cross-sectional survey conducted in four secondary schools in England amongst children aged 11-15 years. We estimate models using both direct and response mapping approaches to predict EQ-5D health utilities and responses. The mean squared error (MSE) and mean absolute error (MAE) were used to assess the predictive accuracy of the models. The models were internally validated on an estimation dataset that included complete PedsQL™ GCS and EQ-5D scores for 559 respondents. Validation was also performed making use of separate data for 337 respondents.
RESULTS: Ordinary least squares (OLS) models that used the PedsQL™ GCS subscale scores, their squared terms and interactions (with and without age and gender) to predict EQ-5D health utilities had the best prediction accuracy. In the external validation sample, the OLS model with age and gender had a MSE (MAE) of 0.036 (0.115) compared with a MSE (MAE) of 0.036 (0.114) for the OLS model without age and gender. However, both models generated higher prediction errors for children in poorer health states (EQ-5D utility score <0.6). The response mapping models encountered some estimation problems because of insufficient data for some of the response levels.
CONCLUSION: Our mapping algorithms provide an empirical basis for estimating health utilities in childhood when EQ-5D data are not available; they can be used to inform future economic evaluations of paediatric interventions. They are likely to be robust for populations comparable to our own (children aged 11-15 years in attendance at secondary school). The performance of these algorithms in childhood populations, which differ according to age or clinical characteristics to our own, remains to be evaluated.

Entities:  

Mesh:

Year:  2014        PMID: 24715604     DOI: 10.1007/s40273-014-0153-y

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  28 in total

1.  Estimating log models: to transform or not to transform?

Authors:  W G Manning; J Mullahy
Journal:  J Health Econ       Date:  2001-07       Impact factor: 3.883

2.  Calculating utility decrements associated with an adverse event: marginal Tobit and CLAD coefficients should be used with caution.

Authors:  Eleanor M Pullenayegum; Jean-Eric Tarride; Feng Xie; Daria O'Reilly
Journal:  Med Decis Making       Date:  2011 Nov-Dec       Impact factor: 2.583

3.  Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients.

Authors:  A Simon Pickard; Maria C De Leon; Thomas Kohlmann; David Cella; Sarah Rosenbloom
Journal:  Med Care       Date:  2007-03       Impact factor: 2.983

Review 4.  A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures.

Authors:  John E Brazier; Yaling Yang; Aki Tsuchiya; Donna Louise Rowen
Journal:  Eur J Health Econ       Date:  2009-07-08

5.  Mapping analyses to estimate health utilities based on responses to the OM8-30 Otitis Media Questionnaire.

Authors:  Helen Dakin; Stavros Petrou; Mark Haggard; Sarah Benge; Ian Williamson
Journal:  Qual Life Res       Date:  2009-11-26       Impact factor: 4.147

6.  Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.

Authors:  Ben van Hout; M F Janssen; You-Shan Feng; Thomas Kohlmann; Jan Busschbach; Dominik Golicki; Andrew Lloyd; Luciana Scalone; Paul Kind; A Simon Pickard
Journal:  Value Health       Date:  2012-05-24       Impact factor: 5.725

7.  Estimating the association between SF-12 responses and EQ-5D utility values by response mapping.

Authors:  Alastair M Gray; Oliver Rivero-Arias; Philip M Clarke
Journal:  Med Decis Making       Date:  2006 Jan-Feb       Impact factor: 2.583

8.  Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study.

Authors:  M F Janssen; A Simon Pickard; Dominik Golicki; Claire Gudex; Maciej Niewada; Luciana Scalone; Paul Swinburn; Jan Busschbach
Journal:  Qual Life Res       Date:  2012-11-25       Impact factor: 4.147

9.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L).

Authors:  M Herdman; C Gudex; A Lloyd; Mf Janssen; P Kind; D Parkin; G Bonsel; X Badia
Journal:  Qual Life Res       Date:  2011-04-09       Impact factor: 4.147

10.  Cross-sectional validity of the EQ-5D-Y as a generic health outcome instrument in children and adolescents with cystic fibrosis in Germany.

Authors:  Daniela Eidt-Koch; Thomas Mittendorf; Wolfgang Greiner
Journal:  BMC Pediatr       Date:  2009-08-28       Impact factor: 2.125

View more
  30 in total

1.  Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.

Authors:  Mónica Hernández Alava; Allan Wailoo; Stephen Pudney; Laura Gray; Andrea Manca
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

2.  Mapping CHU9D Utility Scores from the PedsQLTM 4.0 SF-15.

Authors:  Christine Mpundu-Kaambwa; Gang Chen; Remo Russo; Katherine Stevens; Karin Dam Petersen; Julie Ratcliffe
Journal:  Pharmacoeconomics       Date:  2017-04       Impact factor: 4.981

3.  Cost Effectiveness of Nusinersen in the Treatment of Patients with Infantile-Onset and Later-Onset Spinal Muscular Atrophy in Sweden.

Authors:  Santiago Zuluaga-Sanchez; Megan Teynor; Christopher Knight; Robin Thompson; Thomas Lundqvist; Mats Ekelund; Annabelle Forsmark; Adrian D Vickers; Andrew Lloyd
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

4.  Predicting health utilities for children with autism spectrum disorders.

Authors:  Nalin Payakachat; J Mick Tilford; Karen A Kuhlthau; N Job van Exel; Erica Kovacs; Jayne Bellando; Jeffrey M Pyne; Werner B F Brouwer
Journal:  Autism Res       Date:  2014-09-25       Impact factor: 5.216

5.  Mapping Between the Sydney Asthma Quality of Life Questionnaire (AQLQ-S) and Five Multi-Attribute Utility Instruments (MAUIs).

Authors:  Billingsley Kaambwa; Gang Chen; Julie Ratcliffe; Angelo Iezzi; Aimee Maxwell; Jeff Richardson
Journal:  Pharmacoeconomics       Date:  2017-01       Impact factor: 4.981

6.  Predicting EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities from Older People's Quality of Life Brief Questionnaire (OPQoL-Brief) Scores.

Authors:  Billingsley Kaambwa; Julie Ratcliffe
Journal:  Patient       Date:  2018-02       Impact factor: 3.883

7.  Mapping the Paediatric Quality of Life Inventory (PedsQL™) Generic Core Scales onto the Child Health Utility Index-9 Dimension (CHU-9D) Score for Economic Evaluation in Children.

Authors:  Tosin Lambe; Emma Frew; Natalie J Ives; Rebecca L Woolley; Carole Cummins; Elizabeth A Brettell; Emma N Barsoum; Nicholas J A Webb
Journal:  Pharmacoeconomics       Date:  2018-04       Impact factor: 4.981

8.  Mapping PedsQLTM scores onto CHU9D utility scores: estimation, validation and a comparison of alternative instrument versions.

Authors:  Rohan Sweeney; Gang Chen; Lisa Gold; Fiona Mensah; Melissa Wake
Journal:  Qual Life Res       Date:  2019-11-19       Impact factor: 4.147

9.  The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration.

Authors:  Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

10.  Mapping the Edmonton Symptom Assessment System-Revised: Renal to the EQ-5D-5L in patients with chronic kidney disease.

Authors:  Jiabi Wen; Xuejing Jin; Fatima Al Sayah; Hilary Short; Arto Ohinmaa; Sara N Davison; Michael Walsh; Jeffrey A Johnson
Journal:  Qual Life Res       Date:  2021-07-19       Impact factor: 4.147

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.